Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Four RNAi-Related Patent Applications: Jun 14, 2007

Premium
Title: Methods and Compositions for Gene Silencing
 
Numbers: 20070130653
 
Filed: June 6, 2006
 
Lead Inventor: David Baulcombe, Pioneer Hi-Bred, EI DuPont, Plant Biosciences
 
The patent application, its abstract states, covers “methods and compositions … for reducing the level of expression of a target polynucleotide in an organism. The methods and compositions selectively silence the target polynucleotide through the expression of a chimeric polynucleotide comprising the target for a siRNA (the trigger sequence) operably linked to a sequence corresponding to all or part of the gene or genes to be silenced. In this manner, the final target of silencing is an endogenous gene in the organism in which the chimeric polynucleotide is expressed. In a further embodiment, the miRNA target is that of a heterologous miRNA or siRNA, the latter of which is co-expressed in the cells at the appropriate developmental stage to provide silencing of the final target when and where desired,” the abstract adds. “In a further embodiment, the final target may be a gene in a second organism, such as a plant pest, that feeds upon the organism containing the chimeric gene or genes. Compositions further comprise vectors, seeds, grain, cells, and organisms, including plants and plant cells, comprising the chimeric polynucleotide of the invention.”
 

 
Title: siRNA Targeting Hypoxia-Inducible Factor 1
 
Numbers: 20070128641
 
Filed: Nov. 8, 2006
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
According to the patent application’s abstract, “efficient sequence-specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.”
 

 
Title: siRNA Targeting Ras-Related Nuclear Protein
 
Numbers: 20070128640
 
Filed: Nov. 8, 2006
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
According to the patent application’s abstract, “efficient sequence-specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.”
 

 
Title: Inhibition of Gene Expression by Delivery of Polynucleotides to Animal Cells In Vivo
 
Numbers: 20070128169
 
Filed: Jan. 4, 2007
 
Lead Inventor: David Lewis, Mirus Bio
 
The patent application, its abstract states, claims “a process for intravascular delivery of a polynucleotide to an extravascular cell of a mammal to inhibit gene expression. A polynucleotide containing sequence that is similar to a sequence in the gene to be expressed is made and inserted into a vessel in the mammal. The polynucleotide is delivered to a cell wherein expression of the gene is inhibited.”

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.